Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Diabetes

• Publication date

  1998-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIABETES.47.9.1507PMID 9726242
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria

  2004cited by this paper
• Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy

  1998cited by this paper
• Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus.

  1998cited by this paper
• Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy.

  1997cited by this paper
• Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group.

  1997cited by this paper
• Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy.

  1996cited by this paper
• Angiotensin-converting enzyme gene polymorphism. What to do about all the confusion.

  1996cited by this paper
• Familial factors determine the development of diabetic nephropathy in patients with IDDM

  1996cited by this paper
• Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study

  1996cited by this paper
• Polymorphisms of the renin-angiotensin system genes in progressive renal diseases.

  1996cited by this paper
• Angiotensin-converting enzyme polymorphism in patients with terminal renal failure.

  1996cited by this paper
• Deletion Polymorphism of the Angiotensin I-Converting Enzyme Gene Is Associated with Increased Plasma Angiotensin-Converting Enzyme Activity but Not with Increased Risk for Myocardial Infarction and Coronary Artery Disease

  1996cited by this paper
• Examination of two genetic polymorphisms within the renin-angiotensin system: no evidence for an association with nephropathy in IDDM

  1996cited by this paper
• Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy.

  1995cited by this paper
• Association of ACE gene polymorphism and diabetic nephropathy? The Diabetic Nephropathy Study Group.

  1995cited by this paper
• Rapid methods for population-scale analysis for gene polymorphisms: the ACE gene as an example.

  1995cited by this paper
• Unchanged Incidence of Diabetic Nephropathy in IDDM Patients

  1995cited by this paper
• Lack of Relationship Between an Insertion/Deletion Polymorphism in the Angiotensin I–Converting Enzyme Gene and Diabetic Nephropathy and Proliferative Retinopathy in IDDM Patients

  1995cited by this paper
• Genetic Predisposition to Diabetic Nephropathy: Evidence for a Role of the Angiotensin I–Converting Enzyme Gene

  1994cited by this paper
• Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications.

  1994cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1993cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

  1993cited by this paper
• Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes.

  1993cited by this paper
• Enzyme immunoassay--a new technique for estimating hemoglobin A1c.

  1993cited by this paper
• Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia.

  1991cited by this paper
• Rapid, robust method for measuring low concentrations of albumin in urine.

  1990cited by this paper
• An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.

  1990cited by this paper
• ON ESTIMATING THE RELATION BETWEEN BLOOD GROUP AND DISEASE

  1955cited by this paper

• Pharmacogenomics in cardiac therapy: Personalizing treatment for heart health.

  2025cites this paper
• PHARMACOGENETICS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACEI) AND ANGIOTENSIN II RECEPTOR BLOCKERS (ARB) IN CARDIOVASCULAR DISEASES.

  2024cites this paper
• The Effect of Angiotensin Converting Enzyme (ACE) I/D Polymorphism on Atherosclerotic Cardiovascular Disease and Cardiovascular Mortality Risk in Non-Hemodialyzed Chronic Kidney Disease: The Mediating Role of Plasma ACE Level

  2022cites this paper
• ACE I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes

  2021cites this paper
• Link between ACE I/D Gene Polymorphism and Dyslipidemia in Diabetic Nephropathy: A Case-control Study from Hyderabad, India

  2020cites this paper
• Diabetic Kidney Disease

  2019cites this paper
• Ocular kinetics and safety of intravitreally injected angiotensin converting enzyme inhibitor lisinopril

  2018cites this paper
• Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients

  2017cites this paper
• Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.

  2016cites this paper
• A Physiologic Approach to the Pharmacogenomics of Hypertension.

  2016cites this paper
• Estimation of angiotensin-converting enzyme inhibitors protein binding degree using chromatographic hydrophobicity data.

  2015cites this paper
• Diabetic Nephropathy in Children

  2014cites this paper
• Developments in renal pharmacogenomics and applications in chronic kidney disease

  2014cites this paper
• Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Society for the Study of Diabetes

  2014cites this paper
• ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary

  2014cites this paper
• ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of theEuropeanSocietyofCardiology(ESC)anddevelopedincollaboration

  2014cites this paper
• Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism Contributes High Risk for Chronic Kidney Disease in Asian Male with Hypertension–A Meta-Regression Analysis of 98 Observational Studies

  2014cites this paper
• How can genetics and epigenetics help the nephrologist improve the diagnosis and treatment of chronic kidney disease patients?

  2014cites this paper
• ACE Insertion/Deletion Polymorphism and Diabetic Nephropathy: Clinical Implications of Genetic Information

  2014influential citation
• Association of renin-angiotensin system genes polymorphism with progression of diabetic nephropathy in patients with type 1 diabetes mellitus.

  2014cites this paper
• PHARMACOGENETIC EFFICACY OF PERINDOPRIL IN CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS IN PREDICTION OF DIABETIC NEPHROPATHY

  2013cites this paper
• Évaluation de polymorphismes de p22phox, RAGE et ALOX12 dans la survenue de la néphropathie diabétique chez le type 1 : projet NEPHRODIANOX

  2013cites this paper
• ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

  2013cites this paper
• [ESC guidelines on diabetes, pre-diabetes and diseases of the cardiovascular system developed in cooperation with the EASD].

  2013cites this paper
• RAS Gene Polymorphisms and Renal Responsiveness to RAS Inhibition Therapy in Type 2 Diabetic Asian Indians

  2013cites this paper
• Impact of angiotensin-converting enzyme gene polymorphism on proteinuria and arterial hypertension.

  2013cites this paper
• Evaluation of angiotensin converting enzyme gene polymorphism and susceptibility to bronchial asthma among Egyptians.

  2012cites this paper
• The kallikrein-kinin system in diabetic nephropathy

  2012cites this paper
• Correlation between angiotensin-converting enzyme inhibitors lipophilicity and protein binding data

  2012cites this paper
• Antihypertensive agents for preventing diabetic kidney disease.

  2012cites this paper
• Genetic Basis of Diabetic Nephropathy 697 RATIONALE FOR GENE DISCOVERY IN DIABETIC KIDNEY DISEASE

  2012cites this paper
• ACE insertion/deletion (I/D) polymorphism and diabetic nephropathy.

  2012cites this paper
• Ocena wczesnych markerów uszkodzenia nerek w przebiegu cukrzycy typu 1 u dzieci

  2012cites this paper
• Renal complications of diabetes.

  2012cites this paper
• Lack of association of insertion/deletion polymorphism in angiotensin converting enzyme gene with nephropathy in type 2 diabetic patients in Punjabi population of Pakistan

  2012cites this paper
• Renin-angiotensin system, hypertension, and chronic kidney disease: pharmacogenetic implications.

  2012cites this paper
• Original article ACE I/D gene polymorphism in diabetic nephropathy: Clinical implications

  2011cites this paper
• Genetic polymorphisms related to the renin–angiotensin–aldosterone system and response to antihypertensive drugs

  2010cites this paper
• PharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme

  2010cites this paper
• Genética da predisposição à nefropatia diabética em pacientes com diabetes melito tipo 2

  2010cites this paper
• SNPs: Single Nucleotide Polymorphisms and Pharmacogenomics: Individually Designed Drug Therapy

  2010cites this paper
• Polimorfizm genów poszczególnych składowych układu renina-angiotensyna-aldosteron a progresja przewlekłej choroby nerek Gene polymorphisms of renin-angiotensin-aldosterone system components and the progression of chronic kidney diseases

  2010cites this paper
• Genetics of diabetic nephropathy Bases genéticas da nefropatia diabética

  2010cites this paper
• Genetics of diabetic nephropathy.

  2010cites this paper
• [Gene polymorphisms of renin-angiotensin-aldosterone system components and the progression of chronic kidney diseases].

  2010cites this paper
• Chapter 3 – Diabetic Kidney Disease: Current Challenges

  2010cites this paper
• Risk factors for diabetic nephropathy: intrinsic or extrinsic renal?

  2009cites this paper
• Different Mechanisms for the Progression of CKD with ACE Gene Polymorphisms

  2009cites this paper
• Pharmacogenomics and the prevention of vascular complications in diabetes mellitus

  2009cites this paper
• Pharmacogenetics of cardiovascular drug therapy.

  2009cites this paper
• Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease.

  2009cites this paper
• Review: The problem of diabetic nephropathy and practical prevention of its progression

  2008cites this paper
• [Endothelin system function in diabetic nephropathy].

  2008cites this paper
• [The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy].

  2008cites this paper
• ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.

  2008cites this paper
• Diabetic nephropathy in children and adolescents

  2008cites this paper
• Lack of association between the angiotensin-converting enzyme gene (I/D) polymorphism and diabetic nephropathy in Tunisian type 2 diabetic patients

  2008cites this paper
• [Genetic susceptibility to microangiopathy development in Type 1 diabetes mellitus].

  2008cites this paper
• Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies.

  2008cites this paper
• Papel do sistema endotelina na nefropatia diabética

  2008cites this paper
• Renin–angiotensin system blockade in diabetic nephropathy

  2008cites this paper
• Year : 2005 Does the Angiotensin-converting enzyme ( ACE ) gene insertion / deletion polymorphism modify the response to ACE inhibitor therapy ?-- A systematic review

  2007influential citation
• ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition?

  2007cites this paper
• Towards an integrated approach on RAAS-blockade

  2007cites this paper
• Angiotensin I-converting enzyme: a pathogenetic role in diabetic renal damage?

  2007cites this paper
• Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor

  2007cites this paper
• A PATHOGENETIC ROLE IN DIABETIC RENAL DAMAGE?

  2007cites this paper
• Candidate Genes for Late Diabetic Complications

  2007cites this paper
• Gene and protein markers of diabetic nephropathy.

  2007cites this paper
• Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.

  2006cites this paper
• Factors influencing the risk of diabetic nephropathy : analyses of genes, smoking and diet

  2006cites this paper
• Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy?

  2006cites this paper
• Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients-- interaction with ACE insertion/deletion polymorphism.

  2006cites this paper
• Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease.

  2006cites this paper
• Diabetic Nephropathy in Children and Adolescents

  2005cites this paper
• Association of angiotensin‐converting enzyme DD genotype with 24‐h blood pressure abnormalities in normoalbuminuric children and adolescents with Type 1 diabetes

  2005cites this paper
• Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? – A systematic review

  2005influential citation
• [Pharmacogenetics of angiotensin system in non diabetic nephropathy].

  2005cites this paper
• Pharmacogenetics in drug development

  2005cites this paper
• Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients.

  2005cites this paper
• Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects

  2005cites this paper
• Preventing end stage renal disease in diabetic patients — genetic aspect (part I)

  2005cites this paper
• Predicting the development of diabetic nephropathy and its progression.

  2005cites this paper
• Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.

  2005cites this paper
• The Polypill and Type 2 diabetes

  2004cites this paper
• Influence of Genetic Polymorphisms of the Renin-Angiotensin System on IgA Nephropathy

  2004cites this paper
• Susceptibility genes for diabetic nephropathy in type 1 diabetes : Studies of five genes involved in glucose metabolism, glomerular structure, and blood pressure regulation

  2004cites this paper
• Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy.

  2004cites this paper
• The ACE (I/D) polymorphism and the RAAS in type 1 diabetes mellitus

  2004cites this paper
• Dual blockade of the renin–angiotensin system in diabetic nephropathy

  2004cites this paper
• Polymorphisms in the 5′‐upstream region of the PKCβ gene in Japanese patients with Type 2 diabetes

  2004cites this paper
• Potential therapies mimicking the effects of glucagon‐like peptide‐1 for the treatment of Type 2 diabetes

  2004cites this paper
• What's new in the journals?

  2004cites this paper
• Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.

  2004cites this paper
• Optimizing therapy in the diabetic patient with renal disease: antihypertensive treatment.

  2004cites this paper
• Losartan in diabetic nephropathy

  2004cites this paper
• Microalbuminuria in type 1 diabetes mellitus.

  2004cites this paper
• End‐stage renal failure and management of diabetes

  2004cites this paper
• Pharmacogenetics as related to the practice of cardiothoracic and vascular anesthesia.

  2004cites this paper
• Hypertension in children and adolescents.

  2004cites this paper